We are live on ! Find out more
CBAY

Cymabay Therapeutics
CBAY

Delisted

CBAY was delisted on the 21st of March, 2024.

Back to rankings

1 hedge funds and large institutions have $21.1K invested in Cymabay Therapeutics in 2024 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 198 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 200 → 1 (-199)

100% less funds holding in top 10

Funds holding in top 10: 10 → 0 (-10)

100% less capital invested

Capital invested by funds: $2.73B → $21.1K (-$2.73B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 198

Holders
1
Holders Change
-199
Holders Change %
-99.5%
% of All Funds
0.01%
Holding in Top 10
–
Holding in Top 10 Change
-10
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
198
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
ACA
Avoro Capital Advisors
New York
-$262M
2
BlackRock
BlackRock
New York
-$227M
3
RCM
RA Capital Management
Massachusetts
-$164M
4
Vanguard Group
Vanguard Group
Pennsylvania
-$149M
5
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$144M
Name Holding Trade Value Shares
Change 		Change in
Stake
UBS Group
76
UBS Group
Switzerland
– -$3.27M -138,241 Closed
Qube Research & Technologies (QRT)
77
Qube Research & Technologies (QRT)
United Kingdom
– -$3.14M -132,809 Closed
Manulife (Manufacturers Life Insurance)
78
Manulife (Manufacturers Life Insurance)
Ontario, Canada
– -$3.05M -129,280 Closed
VOYA Investment Management
79
VOYA Investment Management
Georgia
– -$2.91M -122,998 Closed
Two Sigma Advisers
80
Two Sigma Advisers
New York
– -$2.84M -120,200 Closed
RJFSA
81
Raymond James Financial Services Advisors
Florida
– -$2.69M -113,883 Closed
Russell Investments Group
82
Russell Investments Group
United Kingdom
– -$2.63M -111,550 Closed
ACM
83
Altium Capital Management
New York
– -$2.62M -111,000 Closed
AR
84
Advisory Research
Illinois
– -$2.34M -98,985 Closed
CAM
85
ClariVest Asset Management
California
– -$2.28M -96,505 Closed
LPL Financial
86
LPL Financial
California
– -$2.26M -95,601 Closed
New York State Common Retirement Fund
87
New York State Common Retirement Fund
New York
– -$2.24M -95,043 Closed
Royal Bank of Canada
88
Royal Bank of Canada
Ontario, Canada
– -$2.23M -94,260 Closed
Squarepoint
89
Squarepoint
New York
– -$2.2M -93,133 Closed
GTC
90
Ghost Tree Capital
New York
– -$2.13M -90,000 Closed
California State Teachers Retirement System (CalSTRS)
91
California State Teachers Retirement System (CalSTRS)
California
– -$2.1M -88,882 Closed
Legal & General Group
92
Legal & General Group
United Kingdom
– -$2.04M -86,244 Closed
UBS AM
93
UBS AM
Illinois
– -$2.03M -85,842 Closed
Hudson Bay Capital Management
94
Hudson Bay Capital Management
Connecticut
– -$2.01M -85,000 Closed
AG
95
Algert Global
California
– -$2M -84,883 Closed
LPC
96
Lion Point Capital
New York
– -$1.95M -82,425 Closed
Allspring Global Investments
97
Allspring Global Investments
North Carolina
– -$1.89M -80,029 Closed
HWAM
98
Hennion & Walsh Asset Management
New Jersey
– -$1.85M -78,311 Closed
AA
99
ALPS Advisors
Colorado
– -$1.78M -75,374 Closed
SEI Investments
100
SEI Investments
Pennsylvania
– -$1.68M -70,972 Closed
2 3
4
5 6

CBAY Hedge Fund Activity: Q1 2024 in Review

1 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q1 2024, worth a combined $21.1K — down 100% from $2.73B a quarter earlier.

Sellers outnumbered buyers: 198 funds closed out of CBAY and 0 opened new positions — a net loss of 198 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $262M sold.

  • 1 institutional investor held Cymabay Therapeutics (CBAY) as of Q1 2024, down from 200 in Q4 2023.
  • Funds reported $21.1K of Cymabay Therapeutics stock for Q1 2024, down 100% quarter-over-quarter.
  • 0 funds opened new Cymabay Therapeutics positions in Q1 2024 and 198 closed out, a net change of -198 holders.
  • The largest Cymabay Therapeutics seller in Q1 2024 was Avoro Capital Advisors, an estimated $262M sold.

Based on aggregated 13F filings for Q1 2024.